Additional Supporting Information may be found in the online version of this article.

IJC_25665_sm_suppfig-S1.eps681KSupplementary Figure S1. Chemical structures of CTCE-9908 and control scrambled peptide. (a) Structure of CTCE-9908. (b) Structure of control scrambled peptide, SC-9908.
IJC_25665_sm_suppfig-S2.eps395KSupplementary Figure S2. Dosing schedules for different treatment cohorts in MMTV-PyMT mice. (a) Dosing schedule for CTCE-9908 alone trial. (b) Dosing schedule for the combination therapy of CTCE-9908 and docetaxel. Note that docetaxel is started prior to initiation of CTCE-9908 therapy. (c) Dosing schedule for the combination therapy of CTCE-9908 and DC101.
IJC_25665_sm_suppfig-S3.eps6380KSupplementary Figure S3. CXCR4 immunohistochemical staining of mammary tumors from MMTV-PyMT mice. (a), (b) CXCR4 staining of primary mammary tumor.
IJC_25665_sm_suppfig-S4.eps1627KSupplementary Figure S4. Administration of CTCE-9908 to MMTV-PyMT transgenic mice decreases phosphorylated-AKT expression in mammary tumors. (a) Western blot of lysates from mammary tumors from mice treated with the 3 doses of CTCE-9908 as well as with scrambled peptide, showing increasing inhibition of phosphorylated-AKT expression with increasing dose. Total AKT protein expression is used as control in lower row. (b) Bar graph of relative levels of expression of phosphorylated-AKT to total AKT protein in mammary tumors obtained at necropsy from 5 mice from each treatment group. P-values for comparisons between CTCE-9908-25 versus control, P = 0.69; CTCE-9908-50 versus control, P = 0.69; CTCE-9908-100 versus control P = 0.84. Error bars refer to standard error of the mean.

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.